Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

- Revenues From Continuing Operations Increase 25 Percent to $62.6 Million -

- Conference Call Today at 4:30 p.m. Eastern Time -

INCLINE VILLAGE, Nev., May 7 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2009.

Total revenues from continuing operations for the first quarter of 2009 were $62.6 million, a 25 percent increase from $50.2 million for the same period in 2008. The increase was primarily due to increases in royalty revenues driven by higher product sales of Avastin(R), Herceptin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by MedImmune, Inc.

"We were pleased to begin fulfilling the goal of income distribution to stockholders by paying our first post-spin-off dividend in April, a result of the revenues and profits PDL is generating from royalties on a diversified portfolio of successful products," said John McLaughlin, president and chief executive officer of PDL BioPharma. "Our new and focused strategy seeks to optimize our assets to benefit stockholders without the diversion, expense, and considerable risk of research and development."

Total general and administrative expenses from continuing operations in the first quarter of 2009 were $4.7 million compared with $12.7 million in the first quarter of 2008. The decrease was primarily driven by the Company's reduced cost structure. Significant expense items for the first quarter of 2009 included $1.6 million in legal fees for patent prosecution, patent defense and corporate complia
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... 2, 2014  Xencor, Inc. (NASDAQ: ... monoclonal antibodies for the treatment of autoimmune diseases, ... the appointment of Debra Zack , M.D., ... of Lloyd Rowland , senior vice president, ... "Debra,s expertise in biologics clinical development and ...
(Date:9/2/2014)... 2014  Synthetic Biologics, Inc. (NYSE MKT: SYN), ... candidates targeting specific pathogens that cause serious infections ... final preclinical toxicology study of SYN-004. Per U.S. ... study was required to move the Company,s lead ... devastating effects of Clostridium difficile (C. difficile), ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 PMG ... its 11th clinical research site: PMG Research of Rocky ... and operation of the clinical research department at ... PMG’s presence in eastern North Carolina. This new site ... the patients in Rocky Mount and the surrounding communities, ...
(Date:9/2/2014)... , September 2, 2014 Culot ... research and lab management services  BioData, producer ... is pleased to announce the appointment of Louis ... recently served as VP Marketing and Business Development at ... research and clinical applications. Previously, Culot worked ...
Breaking Biology Technology:Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 2Xencor Appoints Debra Zack, M.D., Ph.D., Vice President, Clinical Development and Lloyd Rowland, Senior Vice President, Chief Compliance Officer and General Counsel 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 2Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 3Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 4Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections 5PMG Research Announces the Formation of its Eleventh Site 2PMG Research Announces the Formation of its Eleventh Site 3Louis Culot Appointed as BioData's CEO 2
... 4, 2011 Genesis Biopharma, Inc. (OTC Bulletin Board: ... cancer therapies, today announced that it closed private offerings ... entered into definitive agreements with accredited investors to purchase ... common stock for a purchase price of $1.00 per ...
... Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ) ... Morgan Healthcare Conference on Monday, January 10, 2011.  The ... p.m. Eastern Time).  The session may be accessed through ... Investor Relations page.  An archived version of the presentation ...
... ST. LOUIS, Dec. 30, 2010 Sigma-Aldrich® Corporation ... has acquired all outstanding shares of Cerilliant Corporation ... analytical chemistry product portfolio and to continue to ... leading supplier of high quality reference standards and ...
Cached Biology Technology:Genesis Biopharma Raises $845,000 in Private Financings 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 2Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 3Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio 4
(Date:9/2/2014)... between our immune systems and cholera bacteria, humans may ... phages. In a new study, researchers from Tufts University, ... Health Laboratory, and elsewhere, report that phages can force ... to survive. Importantly, the study published in ... phage predation occurs during human infection. , First author ...
(Date:9/2/2014)... WASHINGTON, September 2, 2014 Best-selling author Sam Kean ... of the Megalodon, the 50-foot super shark that, despite ... long extinct. Learn all about it at http://youtu.be/KhFygIoW_MA ... True Tales of Madness, Love and the History of ... is getting the Reactions treatment in a 10-episode video ...
(Date:9/2/2014)... touch a hot oven, you rapidly pull your hand ... in sensing and responding to such painful stimuli, they ... researchers have made a surprising discovery about the role ... and have built a structural model of the molecule. ... , may help direct new strategies to treat pain ...
Breaking Biology News(10 mins):War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Surprising new role for calcium in sensing pain 2Surprising new role for calcium in sensing pain 3
... identifying a novel compound that primes a plant,s immune system, ... Chicago may be on a path to developing disease-resistant plants. ... team that includes Tim Tschaplinski of the Department of Energy,s ... the immunity response in Arabidopsis, a small flowering plant related ...
... tumors that arise from glial (supporting) cells of the ... grow fine extensions that infiltrate normal brain tissue and, ... surrounding tissue. Therefore, it is almost impossible to remove ... radical surgical removal of the tumor would substantially improve ...
... in German . Europe,s borders have ... from other parts of the world: from the American ... on, hybridise with, parasitise and out-compete native species. They ... landscapes and impact upon agriculture, forestry and fisheries. ...
Cached Biology News:Researchers discover primer to plant defense system 2Fluorescent cancer cells to guide brain surgeons 2Will Europe at last unite to combat thousands of alien invaders? 2Will Europe at last unite to combat thousands of alien invaders? 3
... These versatile vacuum cups provide flexible ... curved, or irregular surfaces. ,PFG: Flat ... Bellows cup ,PCG: Multiple Bellows cup ... from 25 to 200 mm , ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
UGT1A6 (D-20)...
... smallest electronic pressure controller available measuring 26 ... this unit specifically for the analytical instrumentation ... carrier gas flow control, microfluidic flow control, ... focusing, the OEM-EPC offers external pressure sensor ...
Biology Products: